In which patients should denosumab (Prolia) be considered as first-line therapy for osteoporosis?

Updated: Sep 26, 2019
  • Author: Monique Bethel, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Because the overactivity of RANKL is a major factor in bone loss in patients with autoimmune and inflammatory disorders, such as ulcerative colitis, denosumab may become first-line therapy for these patients. [182]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!